Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Razan Medical & Surgical Equipment Trading for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market. This marks Kane's first distribution agreement in the Middle East and third overall for revyve™.
Hussain Malkawi, Managing Director of Razan Medical, expressed enthusiasm about introducing the product to benefit thousands of patients in the UAE. Kane's President & CEO, Marc Edwards, emphasized the company's commitment to commercialization and confidence in the partnership.
Kane has previously announced distribution agreements for revyve™ in the US, Colombia, Costa Rica, and Panama. The company also plans to commercialize the product in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha firmato un accordo di distribuzione triennale con Razan Medical & Surgical Equipment Trading per il suo gel antimicrobico per ferite revyve™ nel mercato della cura delle ferite negli Emirati Arabi Uniti (EAU). Questo segna il primo accordo di distribuzione di Kane in Medio Oriente e il terzo complessivo per revyve™.
Hussain Malkawi, Direttore Generale di Razan Medical, ha espresso entusiasmo nell'introdurre il prodotto per beneficio di migliaia di pazienti negli EAU. Il Presidente e CEO di Kane, Marc Edwards, ha sottolineato l'impegno dell'azienda nella commercializzazione e la fiducia nella partnership.
Kane ha precedentemente annunciato accordi di distribuzione per revyve™ negli Stati Uniti, Colombia, Costa Rica e Panama. L'azienda prevede inoltre di commercializzare il prodotto in Canada dopo aver recentemente ottenuto la certificazione ISO 13485:2016 per il Programma di Audit Unico per Dispositivi Medici (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha firmado un acuerdo de distribución de tres años con Razan Medical & Surgical Equipment Trading para su gel antimicrobiano para heridas revyve™ en el mercado de cuidado de heridas de los Emiratos Árabes Unidos (EAU). Este marca el primer acuerdo de distribución de Kane en Medio Oriente y el tercero en total para revyve™.
Hussain Malkawi, Director General de Razan Medical, expresó entusiasmo por introducir el producto para beneficiar a miles de pacientes en los EAU. El Presidente y CEO de Kane, Marc Edwards, enfatizó el compromiso de la empresa con la comercialización y la confianza en la asociación.
Kane ha anunciado anteriormente acuerdos de distribución para revyve™ en EE. UU., Colombia, Costa Rica y Panamá. La empresa también planea comercializar el producto en Canadá tras obtener recientemente la certificación ISO 13485:2016 para el Programa de Auditoría Única de Dispositivos Médicos (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF)는 아랍 에미리트(UAE) 상처 치료 시장에서 revyve™ 항균 상처 겔에 대한 3년 배급 계약을 Razan Medical & Surgical Equipment Trading과 체결했습니다. 이는 Kane의 중동에서의 첫 배급 계약이며 revyve™에 대한 세 번째 계약입니다.
Razan Medical의 관리 이사인 Hussain Malkawi는 UAE의 수천 명 환자에게 이 제품을 소개하는 데 대한 열정을 표명했습니다. Kane의 사장 겸 CEO인 Marc Edwards는 상업화에 대한 회사의 의지와 파트너십에 대한 신뢰를 강조했습니다.
Kane은 이전에 미국, 콜롬비아, 코스타리카 및 파나마에서 revyve™에 대한 배급 계약을 발표한 바 있습니다. 이 회사는 최근 ISO 13485:2016 의료기기 단일 감사 프로그램(MDSAP) 인증을 받은 후 캐나다에서도 이 제품을 상업화할 계획입니다.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) a signé un accord de distribution de trois ans avec Razan Medical & Surgical Equipment Trading pour son gel antimicrobien pour les plaies revyve™ sur le marché des soins des plaies des Émirats Arabes Unis (EAU). Cela marque le premier accord de distribution de Kane au Moyen-Orient et le troisième en tout pour revyve™.
Hussain Malkawi, Directeur Général de Razan Medical, a exprimé son enthousiasme à introduire le produit pour le bénéfice de milliers de patients aux EAU. Le Président et CEO de Kane, Marc Edwards, a souligné l'engagement de l'entreprise en matière de commercialisation et la confiance dans ce partenariat.
Kane a précédemment annoncé des accords de distribution pour revyve™ aux États-Unis, en Colombie, au Costa Rica et au Panama. L'entreprise prévoit également de commercialiser le produit au Canada après avoir récemment obtenu la certification ISO 13485:2016 pour le Programme d'Audit Unique pour Dispositifs Médicaux (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) hat einen drei Jahre gültigen Vertriebsvertrag mit Razan Medical & Surgical Equipment Trading für das revyve™ antimikrobielle Wundgel auf dem Wundversorgungsmarkt der Vereinigten Arabischen Emirate (VAE) unterzeichnet. Dies stellt den ersten Vertriebsvertrag von Kane im Nahen Osten und den dritten insgesamt für revyve™ dar.
Hussain Malkawi, Geschäftsführer von Razan Medical, äußerte Begeisterung darüber, das Produkt vorzustellen, um Tausenden von Patienten in den VAE zu helfen. Marc Edwards, Präsident und CEO von Kane, betonte das Engagement des Unternehmens für die Kommerzialisierung und das Vertrauen in die Partnerschaft.
Kane hat zuvor Vertriebsvereinbarungen für revyve™ in den USA, Kolumbien, Costa Rica und Panama angekündigt. Das Unternehmen plant außerdem, das Produkt nach dem kürzlichen Erhalt der ISO 13485:2016-Zertifizierung für das Medical Device Single Audit Program (MDSAP) in Kanada zu vermarkten.
- Signed a three-year distribution agreement for revyve™ Antimicrobial Wound Gel in the UAE
- First distribution agreement in the Middle East, expanding market presence
- Third distribution agreement for revyve™, indicating growing product demand
- Plans to commercialize revyve™ in Canada after obtaining ISO 13485:2016 MDSAP certification
- None.
Company’s First Distribution Agreement in Middle East
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Razan Medical & Surgical Equipment Trading LLC (“Razan Medical” or “Razan Medical Trading”) for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market.
“At Razan Medical, we are dedicated to introducing the latest innovations in the medical device industry. Our commitment to advancing wound care — from prevention to healing — has led us to pursue this partnership with Kane,” said Hussain Malkawi, Managing Director of Razan Medical. “Our collaboration will bring forth an exceptional product to the UAE market which will benefit thousands of patients. We are thrilled about this partnership and look forward to a successful and impactful collaboration.”
“Kane continues to deliver on its commitment to commercialization with this first distribution agreement in the Middle East,” said Marc Edwards, President & CEO. “We’re looking forward to partnering with Razan Medical to bring revyve™ to market in the UAE and we are confident that it is in great hands.”
This is Kane’s third distribution agreement for revyve™. Kane had previously announced agreements with ProgenaCare Global LLC for the US wound care market and Salud Pharma S.A. for Colombia, Costa Rica and Panama. Kane also recently announced its intent to commercialize revyve™ in Canada following the obtention of its ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. DispersinB®, Aledex™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
About Razan Medical Trading
Established in 2015 by Mr. Hussain Malkawi as the trading arm of Razan Medical Group, Razan Medical Trading serves as a local (UAE) and regional distributor of medical equipment and consumables in the MENA region. With over 30 years of expertise managing multinational companies in the Middle East and Africa, we provide a wealth of knowledge and experience to ensure a visible and influential presence in the region.
For more information:
| Marc Edwards | Ray Dupuis | |||
| Chief Executive Officer | Chief Financial Officer | |||
| Kane Biotech Inc | Kane Biotech Inc | |||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | |||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What is the new distribution agreement Kane Biotech (KNBIF) has signed for revyve™ Antimicrobial Wound Gel?
How many distribution agreements does Kane Biotech (KNBIF) now have for revyve™?
What certification has Kane Biotech (KNBIF) recently obtained for revyve™?
Who is the Managing Director of Razan Medical, Kane Biotech's (KNBIF) new distribution partner in the UAE?
